Dr. Tzu-Ming Pan, head of technology of SunWay Biotech, was invited as speaker in 4th World Congress and Expo on Traditional and Alternative Medicine.
During 14-16 March 2021, 4th World Congress and Expo on Traditional and Alternative Medicine is organized in collaboration with Taipei Chinese Medical Association, Meridian World Health Organization Alliance (MWHOA), Chang Gung University, Tzu Chi University, I Shou University, and China Medical University. The Congress focused on the theme “World Health for everyone with local Wisdom and Resources,” with the domestic well-known speakers and international scholars were invited to publish the research of traditional and alternative medical therapies for global health issues through this online conference. The Head of Technology of SunWay Biotech, Dr. Tzu-Ming Pan, was invited as a speaker by Taipei Chinese Medical Association and Global Scientific Guild to announce at the conference that heart health supplement plays an important role for global health. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death globally. WHO says that about 17.9 million people worldwide died from CVDs in 2016 alone, representing 31 percent of all global deaths. Moreover, amid the COVID-19 crisis, the global market for Heart Healthy Ingredients estimated at US$16.6 Billion in the year 2020, is projected to reach a revised size of US$24.8 Billion by 2027, growing at a of 5.9% over the analysis period 2020-2027. Red yeast rice, as a dietary supplement ingredient for heart health, is prized for its ability to lower cholesterol […]
SunWay 2020 annual revenue was 314 million and will be listed on Taiwan Emerging Stock Market on January 18, 2021.
On January 12, SunWay Biotech Co., LTD. (1271) was invited by Fubon Securities Co., Ltd. to participate in the institutional investor conference. John Pan, President of SunWay Biotech, introduced two main ingredients-ANKASCIN 568-R and Vigiis 101-LAB probiotics and their application, and announced that SunWay Biotech will be listed on Taiwan Emerging Stock Market on January 18, 2021.
Congratulations! The innovation of Professor Tzu-Ming Pan and SunWay Biotech is awarded “Advanced National Innovation Award” on 1 Dec 2020!
We, Innovators The innovation of Professor Tzu-Ming Pan and SunWay Biotech “The Red Yeast Rice- Improvement of Memory and Learning Abilities of Alzheimer’s Patients” was awarded the National Innovation Award in 2008. With the continuous innovation, specific research, and development process for promotion worldwide, this application has been twice awarded the “Advanced National Innovation Award” on 1 Dec 2020! Advanced National Innovation Award Advanced National Innovation Award Advanced National Innovation Award Advanced National Innovation Award
In the annual “Taiwan BIO Awards”, SunWay Biotech passed all the steps from the preliminary review to the final one by its multinational patents and strain-based market planning. SunWay Biotech has stood out from 55 biotechnology industry companies and awarded “Taiwan BIO Awards- Emerging Company of the Year“ in 2020! BIO Asia-Taiwan 2020 International Conference & Exhibition SunWay Biotech company is awarded by President Tsai, Ing-Wen Professor Pan, Tzu-Ming introduced the history of SunWay Biotech company Speech of Professor Pan, Tzu-Ming Professor Pan, Tzu-Ming SunWay Biotech is awarded “Taiwan Bio Awards” in 2020.
[Emergency Notice!!] In Taiwan, there are counterfeit red yeast rice bottled products which have been sold via the internet. The fake bottled product is definitely not the original red yeast rice product of Professor Tzu-Ming Pan (娘家大紅趜). As the material provider and manufactory of original red yeast rice product, SunWay Biotech (SunWay) urges everyone should not only stop buying the fake product but also stop forwarding the information of the fake bottled product. The fake bottled product might do harm to your own health. Both SunWay and authorized reseller shall protect our intellectual properties. Please be assured that we would investigate all leads of the illegal activity and shall take appropriate legal action against the mean and unworthy sellers. The counterfeit/fake product (please see the left one) and original product (right one) are shown in the figure below. Please share this emergency notice and keep supporting the original red yeast rice product. Please purchase the product from the official authorized channels, or call the customer service directly at +886-800066099. If you have any questions, please do not hesitate to contact us on the FB or SunWay’s website. Thank you for your help.
According to the World Health Organization (WHO), cardiovascular disease (CVD) is the leading cause of death globally. Some of the risk factors for CVD include high cholesterol, hypertension and diabetes. Red yeast rice has been shown to help lower cholesterol and improve blood circulation, as well as positively impacting blood lipids, blood glucose and blood pressure. This Whitepaper by SunWay Biotech Co. Ltd. explores the potential of ANKASCIN® 568-R red yeast rice extract—which does not contain monacolin K (statin)—in heart health dietary supplement applications. • The CDC attributes one-quarter of American deaths annually to CVD, with no gender bias. • U.S. sales of red yeast rice dietary supplements were estimated at $49 million in 2015. • The U.S. heart health ingredient market is predicted to reach $15.2 billion by 2018 Source: Natural Products Insider
This year, we are going to exhibit at SupplySide West 2017 in Las Vegas during September 27-28. Here you will see our multi-functional dietary ingredients － ANKASCIN 568-R and Vigiis 101-LAB.
Interview from PharmaBoardRoom: George J. Lee, Ph.D. – Chairman; Tzu-Ming Pan, Ph.D – Vice Chairman and Chief Technology and Science Officer, SunWay Biotech, Taiwan
George Lee and Tzu-Ming Pan introduce SunWay Biotech’s groundbreaking red yeast rice extract, ANKASCIN® 568-R, which has been recognized as a New Dietary Ingredient by the US FDA. SunWay Biotech is now bringing this unique product onto the global stage and are considering developing a pharmaceutical product based on the same compounds.
2016 Taiwan-ASEAN Investment Strategy Partner Forum Held as Part of New Southbound Policy: Connect with ASEAN to Create New Business Opportunities
The Taiwan-ASEAN Investment Strategy Partner Forum, organized by the Ministry of Economic Affairs’s (MOEA) Department of Investment Services, was held at the Taipei International Conference Center today (the 13th).